MGRO — MustGrow Biologics Share Price
0.000.00%
Last trade - 00:00- CA$55.77m
- CA$53.29m
- CA$0.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 25.71 | ||
| Price to Tang. Book | 34.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 140.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -202.94% | ||
| Return on Equity | -126.1% | ||
| Operating Margin | -1284.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | 0.01 | 0.01 | 4.71 | 0.4 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MustGrow Biologics Corp. is a fully integrated provider of biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, it offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. It develops mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Its TerraSante is Organic Materials Review Institute (OMRI Listed) and Organic Input Material (OIM) registered biofertility product in California, Florida, Arizona, Idaho, Oregon, and Washington. TerraSante provides mustard proteins and carbohydrates to feed the soil microbes.
Directors
- Bradley Munro NEC
- Corey Giasson PRE
- Todd Lahti CFO
- Colin Bletsky COO
- David Borecky IND
- Thomas Flow IND (43)
- Matt Kowalski IND
- Brian Quigley IND (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 2nd, 2014
- Public Since
- July 10th, 2019
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 51,640,610
- Address
- 1005-201 1st Ave S, Saskatoon, S7K 1J5
- Web
- https://mustgrow.ca/
- Phone
- +1 3066682652
- Auditors
- Ernst & Young LLP
Upcoming Events for MGRO
Q1 2025 MustGrow Biologics Corp Earnings Release
MustGrow Biologics Corp Annual Shareholders Meeting
MustGrow Biologics Corp Annual Shareholders Meeting
Q2 2025 MustGrow Biologics Corp Earnings Release
Q2 2025 MustGrow Biologics Corp Earnings Release
Similar to MGRO
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
What is the MustGrow Biologics share price?
As of Today at 22:10 UTC, shares in MustGrow Biologics are trading at CA$1.08. This share price information is delayed by 15 minutes.
How has the MustGrow Biologics share price performed this year?
Shares in MustGrow Biologics last closed at CA$1.08 and the price had moved by -1.82% over the past 365 days. In terms of relative price strength the MustGrow Biologics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -12.71% over the past year.
What are the analyst and broker recommendations for MustGrow Biologics?
There is no consensus recommendation for this security.
Find out moreWhat is the MustGrow Biologics dividend yield?
MustGrow Biologics does not currently pay a dividend.
Does MustGrow Biologics pay a dividend?
MustGrow Biologics does not currently pay a dividend.
When does MustGrow Biologics next pay dividends?
MustGrow Biologics does not currently pay a dividend.
How do I buy MustGrow Biologics shares?
To buy shares in MustGrow Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MustGrow Biologics?
As of the previous close price of CA$1.08, shares in MustGrow Biologics had a market capitalisation of CA$55.77m.
Where are MustGrow Biologics shares listed?
Here are the trading details for MustGrow Biologics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: MGRO
What kind of share is MustGrow Biologics?
Based on an overall assessment of its quality, value and momentum MustGrow Biologics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MustGrow Biologics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the MustGrow Biologics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MustGrow Biologics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -52.49%.
As of the last closing price of CA$1.08, shares in MustGrow Biologics were trading -12.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MustGrow Biologics PE Ratio?
The MustGrow Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MustGrow Biologics?
MustGrow Biologics' management team is headed by:
- Bradley Munro - NEC
- Corey Giasson - PRE
- Todd Lahti - CFO
- Colin Bletsky - COO
- David Borecky - IND
- Thomas Flow - IND
- Matt Kowalski - IND
- Brian Quigley - IND